{'52WeekChange': -0.13951933,
 'SandP52WeekChange': 0.0644362,
 'address1': '4000 Shoreline Court',
 'address2': 'Suite 250',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.28,
 'askSize': 800,
 'averageDailyVolume10Day': 150612,
 'averageVolume': 188239,
 'averageVolume10days': 150612,
 'beta': None,
 'beta3Year': None,
 'bid': 9.07,
 'bidSize': 900,
 'bookValue': 3.34,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.86,
 'dayLow': 12.805,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.812,
 'enterpriseToRevenue': 26.686,
 'enterpriseValue': 213784144,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 16.644,
 'fiftyTwoWeekHigh': 25.02,
 'fiftyTwoWeekLow': 10.27,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 8329056,
 'forwardEps': -2.04,
 'forwardPE': -6.318628,
 'fromCurrency': None,
 'fullTimeEmployees': 67,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.13218,
 'heldPercentInstitutions': 0.77353996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/harpoontx.com',
 'longBusinessSummary': 'Harpoon Therapeutics, Inc., a clinical-stage '
                        'immunotherapy company, engages in the development of '
                        'a novel class of T cell engagers that harness the '
                        "power of the body's immune system to treat patients "
                        'suffering from cancer and other diseases in the '
                        "United States. The company's lead TriTAC product "
                        'candidate is HPN424 that is in Phase I clinical trial '
                        'for the treatment of metastatic castration-resistant '
                        'prostate cancer. It also develops HPN536, which is in '
                        'Phase I/IIa clinical trial for the treatment of '
                        'ovarian cancer and other MSLN-expressing tumors; '
                        'HPN217 for the treatment of multiple myeloma; and '
                        'HPN328 for the treatment of SCLC. The company has a '
                        'collaboration agreement with AbbVie Biotechnology '
                        'Ltd. Harpoon Therapeutics, Inc. was founded in 2015 '
                        'and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'Harpoon Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 322222944,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_413195889',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -54545000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.86,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 443 7400',
 'previousClose': 13.64,
 'priceHint': 2,
 'priceToBook': 3.8592815,
 'priceToSalesTrailing12Months': 40.22256,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.86,
 'regularMarketDayLow': 12.805,
 'regularMarketOpen': 13.86,
 'regularMarketPreviousClose': 13.64,
 'regularMarketPrice': 13.86,
 'regularMarketVolume': 143318,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24997900,
 'sharesPercentSharesOut': 0.0179,
 'sharesShort': 446271,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 211265,
 'shortName': 'Harpoon Therapeutics, Inc.',
 'shortPercentOfFloat': 0.042600002,
 'shortRatio': 2.41,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'HARP',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.248,
 'twoHundredDayAverage': 14.923525,
 'volume': 143318,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.harpoontx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}